3D Spheroid Culture for Personalized Drug Sensitivity Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining drug sensitivity in patients fail to account for individual variations, as they rely on collective cell properties and do not accurately replicate the in vivo environment, leading to ineffective chemotherapy and potential progression of cancer due to non-personalized treatment approaches.
Innovation Solution
A method involving the direct culture of cells from primary biological tissue or cell-containing bodily fluids into three-dimensional spheroids, allowing for the screening of therapeutic responses to various compounds without intermediate cell culture steps, thereby mimicking in vivo conditions and enabling personalized treatment regimes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cell culture methods are used to test drug sensitivity, then the testing process is simplified and standardized, but the results fail to accurately reflect individual patient responses and in vivo conditions
Solution Approach 1:
The patent transitions from conventional two-dimensional monolayer cell culture to three-dimensional spheroid culture. This dimensional change enables cells to self-organize into spherical structures that better mimic in vivo tissue architecture, improving the accuracy of drug response predictions while maintaining a relatively simple culture protocol using hanging drop or ultra-low attachment plates
Solution Approach 2:
The patent changes key culture parameters including substrate attachment properties (using ultra-low attachment surfaces), oxygen concentration (culturing in physiological oxygen levels of 2-5% O2), and extracellular matrix composition. These parameter changes enable spheroid formation and maintain cellular characteristics that reflect in vivo conditions, thereby improving measurement precision without excessive complexity
2Productivity
If standardized treatment protocols are applied to all patients, then treatment implementation is efficient and consistent, but individual variations in drug sensitivity are not accounted for
Solution Approach 1:
The patent performs preliminary drug sensitivity testing on patient-derived cells cultured as spheroids before administering chemotherapy. By pre-testing multiple drug candidates on the patient's own cells in a high-throughput manner, the system identifies effective treatments in advance, enabling personalized therapy selection without delaying treatment initiation
Solution Approach 2:
The patent creates in vitro copies of patient tumor tissue using spheroid cultures derived from biopsy samples. These cellular copies retain the genetic and phenotypic characteristics of the original tumor, allowing drug responses to be tested on patient-specific models rather than relying on population-averaged data, thereby improving treatment reliability
3Measurement precision
If three-dimensional spheroid culture is implemented to mimic in vivo conditions, then the biological relevance of testing is improved, but the culture methodology becomes more complex
Solution Approach 1:
The patent employs ultra-low attachment culture plates that enable cells to self-assemble into spheroids without external intervention or complex manipulation. The special plate surface geometry causes cells to aggregate into three-dimensional structures automatically, eliminating the need for manual spheroid formation techniques and simplifying the overall culture protocol
Solution Approach 2:
The patent uses specialized ultra-low attachment plate surfaces as an intermediary between conventional culture methods and three-dimensional spheroid formation. This intermediary substrate provides the physical conditions necessary for spheroid self-assembly while maintaining ease of operation and compatibility with standard cell culture protocols
4Adaptability or versatility
If primary patient tissue is used directly for testing, then individual patient characteristics are preserved, but the difficulty of establishing cultures from primary isolates increases
Solution Approach 1:
The patent uses three-dimensional spheroid culture to improve the adaptability of primary tissue cultures. The 3D environment better supports the survival and growth of primary cells by mimicking in vivo tissue architecture and cell-cell interactions, thereby increasing the success rate of establishing cultures from primary patient samples without requiring complex culture conditions
Data Source
Figure 1
AI summary
The invention relates to methods for testing the response of spheroids to exposure with therapeutics. Preferably the spheroids are derived from primary isolate biological tissue and/or cell-containing bodily fluid. Further embodiments relate to spheroid sections and arrays including kits suitable for carrying out the method according to the present invention.